P inhibitor

Powers, M. V. Workman, P. Inhibitors of the heat shock response biology and pharmacology. FEBS Lett. 2007, 581, 3758-3769. 

Correia MA, Ortiz de Montellano P Inhibitors of cytochrome P-450 and possibilities for their therapeutic application. In Ruckpaul (editor) Frontiers in Biotransformation, vol 8. Taylor Francis, 1993. 

Testa B, Jenner P. Inhibitors of cytochrome P-450s and their mechanisms of action. DrugMetab Rev 1981 ... 

Case 1 (varied [A], nonsaturating [B], P inhibitor) From rule (b) above, noncompetitive or mixed inhibition will be obtained, as A and P bind to different forms of the enzyme (E and EO, respectively) linked by reversible interconversions. 

Case 2 (varied [A], saturating [B], P inhibitor) In this case, the link between E and EO is irreversible (because B is present at saturating levels) hence, from rule (c) above, uncompetitive inhibition will be obtained. 

The PKC-DRS Smdy Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy initial results of the Protein Kinase C P Inhibitor Diabetic Retinopathy Smdy (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005 54 2188. 

Saquinavir (31)was the first HIV-P inhibitor approved for human use. Figure 10.9B... 

HIV-P inhibitor drugs are less than ideal, the search for better ones has continued. Many of the deficits arise from the large size and pep-tidic nature of the inhibitors. Another early... 

Another C2 symmetric HIV-P inhibitor, discovered at Dupont Merck is compound (36) (DMP-450). This was one of a series of cyclic ureas designed to interact with both the aspar-tyl carboxylatesand the He50 and Ile50 backbone amides that hydrogen bond with the flap... 

One of problems common to many of the HIV-P inhibitors already discussed is their... 

Several other approved AIDS drugs that act by inhibition of HIV-P have also been developed through use of SBDD methods. Compound (42) (amprenavir, Agenerase, also known as VX-478) is the most recent addition to the HIV-P inhibitors approved for human antiviral treatment, and differs significantly from earlier inhibitors. Compound (42) was specifically designed by Vertex scientists to minimize molecular weight to increase oral... 

ML. Constanzer, C.M. Chavez-Eng, J. Dm, W.F. Kline, B.K. Matuszewski, Determination of a novel substance P inhibitor in human plasma by LC-APCI-MS detection using single and triple quadrupole detectors, J. Chromatogr. B, 807 (2004) 807. 

Proline endopeptidase (EC 3.4.-24.26 post-proline endopeptidase TRH deamidating enzyme) is a soluble serine protease. Notable substrates include angiotensin I, angiotensin II, bradykinin. LH-RH, neurotensin and substance P. Inhibitors include Cbz-Pro-Prolinal. 

Inhibitors specific for PKC-p have a more favorable toxicity profile. In fact, in a study by Aiello et al. (52), the effect of VEGF on retinal vascular permeability appeared to be mediated predominantly by the p-isoform of PKC. There was >95% inhibition of VEGF-induced permeability after administration of a PKC p-isoform-selective inhibitor (50). Studies are currently being conducted with a new PKC-p inhibitor, known as ruboxistaurin mesylate. Thus far, based on animal... 

Porcelli, M., Casu, M., Lai, A., Saba, G., Pinori, M., Cappelletti, S. and Mascagni, P. (1999) Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor. Biopolym. 50 211-219. 

Another substance P inhibitor was isolated from the mycelial extract — fiscalin B (10), which was originally isolated from Neosartorya fischeri by Sterling -Winthrop labs [46]. The fiscalins are structurally similar to the tremorgenic tryptoquivaline mycotoxins produced by Aspergillus clavatus [47] and A. fumigatus [48]. Fiscalin B was purified by reverse phase HPLC (Rainin C8 semipreparative, 50% methanol/water - 100% methanol) of the initial silica gel fraction 12. 

Abbreviations AUC, area under the curve in the presence of an inhibitor AUC, area under the curve in the absence of an inhibitor CLi y, intrinsic clearance in the presence of an inhibitor CLi , intrinsic clearance in the absence of an inhibitor , fraction of dose metabolized via CYPs , p45o, fraction of total CYP-mediated metabolism catalyzed by inhibited CYP form p], inhibitor concentration [S], substrate concentration Kj, dissociation constant of inhibitor nzyme complex K, dissociation constant of substrate-enzyme complex knacu rate constant of CYP inactivation Kisg, rate constant of CYP degradation or turnover Ki, half maximal rate of inactivation (exact physical meaning is not defined). 

Heisig P. Inhibitors of bacterial topoisomerases Mechanisms of action and resistance and clinical aspects. Planta Med 2001 67 3-12. 

Figure 5.10. Demonstration of the four basic types of inhibitions of enzyme kinetics in Lineweaver-Burk plots (see Fig. 4.24c) (a) competitive, (b) noncompetitive, (c) uncompetitive, and (d) substrate inhibition. The parameters and can be estimated from the intercepts and slope of the line with p — 0, where p = inhibitor concentration.

---